nifedipine CR tablets (Adalat) — Competitive Intelligence Brief

nifedipine CR tablets (Adalat) (nifedipine CR tablets (Adalat)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule

Target snapshot

nifedipine CR tablets (Adalat) (nifedipine CR tablets (Adalat)) — Shanghai Shyndec Pharmaceutical Co., Ltd.. Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nifedipine CR tablets (Adalat) TARGET	nifedipine CR tablets (Adalat)	Shanghai Shyndec Pharmaceutical Co., Ltd.	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
trandolapril/verapamil	trandolapril/verapamil	Abbott	marketed	ACE inhibitor / calcium channel blocker combination	Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels
Amlodipine + Indapamide	Amlodipine + Indapamide	Centre for Chronic Disease Control, India	marketed	Calcium channel blocker + Thiazide-like diuretic combination	L-type voltage-gated calcium channels (amlodipine); sodium-chloride cotransporter (indapamide)
Losartan and Amlodipine	Losartan and Amlodipine	Centro Universitario de Ciencias de la Salud, Mexico	marketed	Angiotensin II receptor antagonist + Calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Amlodipine+standard antihypertensive therapy	Amlodipine+standard antihypertensive therapy	Beijing Tiantan Hospital	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine plus Metformin	Amlodipine plus Metformin	Third Military Medical University	marketed	Combination therapy: calcium channel blocker + biguanide antidiabetic	L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)
Felodipine add Irbesartan	Felodipine add Irbesartan	LanZhou University	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type voltage-gated calcium channels; AT1 angiotensin II receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

1. Bayer · 2 drugs in this class
2. Beijing Tiantan Hospital · 2 drugs in this class
3. GlaxoSmithKline · 1 drug in this class
4. Guangzhou First People's Hospital · 1 drug in this class
5. Organon and Co · 1 drug in this class
6. Peking University First Hospital · 1 drug in this class
7. Pfizer Inc. · 1 drug in this class
8. SK Chemicals Co., Ltd. · 1 drug in this class
9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class